VILLA GUARDIA (COMO), Italy--(BUSINESS WIRE)--Gentium S.p.A. (Nasdaq: GENT) announced today that results from the Company’s Phase II/III Pediatric Prevention trial and Phase III Treatment trial for Defibrotide of Hepatic Veno-Occlusive Disease will be presented at American Society of Hematology Conference (ASH), December 5-8 in New Orleans. The results of these trials will be highlighted in two separate oral presentations on Monday, December 7, 2009 during the session, “Clinical Care
For more information, please visit
http://www.businesswire.com/news/home/20091116005462/en